Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.38 |
| ▸ | BCR | P11274 | 3/20 | 0.38 |
| ▸ | GBA1 | P04062 | 4/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31713632 | 0.91 | HSD11B1 (0.38) | ABL1BCRGBA1HSD11B1GAA | |
| SCHEMBL31713402 | 0.91 | ABL1 (0.38) | ABL1BCRGBA1HSD11B1GAA | |
| SCHEMBL31713321 | 0.89 | ABL1 (0.37) | ABL1BCRGBA1HSD11B1GAA | |
| SCHEMBL31713696 | 0.88 | ABL1 (0.36) | ABL1BCRGBA1HSD11B1GAA | |
| SCHEMBL31713324 | 0.87 | ABL1 (0.39) | ABL1BCRGBA1HSD11B1GAA | |
| SCHEMBL31713493 | 0.87 | ABL1 (0.38) | ABL1BCRGBA1HSD11B1GAA | |
| SCHEMBL31713569 | 0.86 | ABL1 (0.38) | ABL1BCRGBA1HSD11B1GAA | |
| SCHEMBL31713278 | 0.85 | — | — | |
| SCHEMBL31713789 | 0.85 | ABL1 (0.38) | ABL1BCRGBA1HSD11B1GAA | |
| SCHEMBL31713749 | 0.85 | ABL1 (0.36) | ABL1BCRGBA1HSD11B1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYSOWAY THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | STOML2, ATP2A3, ATP2A1 | ABL1 4069/4885BCR 282/4885GBA1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.